_id
691301b7ccc777a4e85d794b
Ticker
INCPF
Name
InnoCare Pharma Limited
Exchange
PINK
Address
Building 8, Beijing, China, 102206
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.innocarepharma.com
Description
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-192, a pan-FGFR inhibitor that is in a registrational trial for the treatment of solid tumor patients, including cholangiocarcinoma; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase II clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, the company develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, the company offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. The company has a clinical collaboration with ArriVent Biopharma, Inc. to evaluate the anti-tumor activity and safety of ICP-189 combined with furmonertinib in patients with advanced non-small cell lung cancer. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Last Close
2.05
Volume
-
Current Price
2.05
Change
0
Last Updated
2026-01-04T15:12:47.443Z
Image
-
Ipo Date
-
Market Cap
3612423680
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.8316272727272728
Sentiment Sources
11
Current Quarter
2025-09-30
Revenue
53880370
Cost Of Revenue
6802119
Gross Profit
47078251
Operating Expenses
58820730
Operating Income
-11742478
Interest Expense
2034254
Pretax Income
-4715232
Net Income
-4817377
Eps
-0.002732553544192528
Dividends Per Share
-
Shares Outstanding
1493798235
Income Tax Expense
381266
EBITDA
-2639143
Operating Margin
-21.793610548702617
Total Other Income Expense Net
7027246
Cash
957529394
Short Term Investments
28106308
Receivables
64545095
Inventories
17585447
Total Current Assets
1118018407
Property Plant Equipment
106002354
Total Assets
1337092394
Payables
21054709
Short Term Debt
45589305
Long Term Debt
-
Total Liabilities
399498355
Equity
935755055
Bs_currency_symbol
-
Depreciation
-
Change In Working Capital
-
Cash From Operations
-114179
Capital Expenditures
1946709
Cash From Investing
-56912642
Cash From Financing
15471189
Net Change In Cash
-16445753
Cf_currency_symbol
-
PE
-
PB
3.8621899847498016
ROE
-0.5148117527401441
ROA
-0.36028751802173514
FCF
-2060888
Fcf Percent
-0.03824932902279624
Piotroski FScore
1
Health Score
30
Deep Value Investing Score
3.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
3.5
Net Net Investing Score
3
Quality Investing Score
2.5
Value Investing Score
3.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
53880370
Quarters > 0 > income Statement > cost Of Revenue
6802119
Quarters > 0 > income Statement > gross Profit
47078251
Quarters > 0 > income Statement > operating Expenses
58820730
Quarters > 0 > income Statement > operating Income
-11742478
Quarters > 0 > income Statement > interest Expense
2034254
Quarters > 0 > income Statement > pretax Income
-4715232
Quarters > 0 > income Statement > net Income
-4817377
Quarters > 0 > income Statement > eps
-0.002732553544192528
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
1762957952
Quarters > 0 > income Statement > income Tax Expense
381266
Quarters > 0 > income Statement > EBITDA
-2639143
Quarters > 0 > income Statement > operating Margin
-21.793610548702617
Quarters > 0 > income Statement > total Other Income Expense Net
7027246
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
957529394
Quarters > 0 > balance Sheet > short Term Investments
28106308
Quarters > 0 > balance Sheet > receivables
64545095
Quarters > 0 > balance Sheet > inventories
17585447
Quarters > 0 > balance Sheet > total Current Assets
1118018407
Quarters > 0 > balance Sheet > property Plant Equipment
106002354
Quarters > 0 > balance Sheet > total Assets
1337092394
Quarters > 0 > balance Sheet > payables
21054709
Quarters > 0 > balance Sheet > short Term Debt
45589305
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
399498355
Quarters > 0 > balance Sheet > equity
935755055
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-4817377
Quarters > 0 > cash Flow > depreciation
-
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-114179
Quarters > 0 > cash Flow > capital Expenditures
1946709
Quarters > 0 > cash Flow > cash From Investing
-56912642
Quarters > 0 > cash Flow > cash From Financing
15471189
Quarters > 0 > cash Flow > net Change In Cash
-16445753
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.002732553544192528
Quarters > 0 > ratios > PB
3.8621899847498016
Quarters > 0 > ratios > ROE
-0.5148117527401441
Quarters > 0 > ratios > ROA
-0.36028751802173514
Quarters > 0 > ratios > FCF
-2060888
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-0.03824932902279624
Quarters > 0 > health Score
30
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
350171033
Quarters > 1 > income Statement > cost Of Revenue
40646900
Quarters > 1 > income Statement > gross Profit
309524133
Quarters > 1 > income Statement > operating Expenses
356803497
Quarters > 1 > income Statement > operating Income
-47279364
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-46977638
Quarters > 1 > income Statement > net Income
-48059040
Quarters > 1 > income Statement > eps
-0.03964030366101931
Quarters > 1 > income Statement > dividends Per Share
-8423399
Quarters > 1 > income Statement > shares Outstanding
1212378200
Quarters > 1 > income Statement > income Tax Expense
3136122
Quarters > 1 > income Statement > EBITDA
-88694774
Quarters > 1 > income Statement > operating Margin
-13.501791851526452
Quarters > 1 > income Statement > total Other Income Expense Net
301726
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
7056194527
Quarters > 1 > balance Sheet > short Term Investments
39655169
Quarters > 1 > balance Sheet > receivables
392271088
Quarters > 1 > balance Sheet > inventories
117754237
Quarters > 1 > balance Sheet > total Current Assets
7844745728
Quarters > 1 > balance Sheet > property Plant Equipment
775396106
Quarters > 1 > balance Sheet > total Assets
9363533203
Quarters > 1 > balance Sheet > payables
178053422
Quarters > 1 > balance Sheet > short Term Debt
174348494
Quarters > 1 > balance Sheet > long Term Debt
1033900000
Quarters > 1 > balance Sheet > total Liabilities
2645283237
Quarters > 1 > balance Sheet > equity
6703162568
Quarters > 1 > balance Sheet > currency_symbol
CNY
Quarters > 1 > cash Flow > net Income
-48059040
Quarters > 1 > cash Flow > depreciation
58998332
Quarters > 1 > cash Flow > change In Working Capital
-88287604
Quarters > 1 > cash Flow > cash From Operations
-118340608
Quarters > 1 > cash Flow > capital Expenditures
9873181
Quarters > 1 > cash Flow > cash From Investing
-15926649
Quarters > 1 > cash Flow > cash From Financing
-4422920
Quarters > 1 > cash Flow > net Change In Cash
-142921306
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.03964030366101931
Quarters > 1 > ratios > PB
0.37077652299003583
Quarters > 1 > ratios > ROE
-0.7169606810586308
Quarters > 1 > ratios > ROA
-0.5132575381331727
Quarters > 1 > ratios > FCF
-128213789
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-0.3661461883399133
Quarters > 1 > health Score
33
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
381263139
Quarters > 2 > income Statement > cost Of Revenue
36066440
Quarters > 2 > income Statement > gross Profit
345196699
Quarters > 2 > income Statement > operating Expenses
328802649
Quarters > 2 > income Statement > operating Income
16394050
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
16394050
Quarters > 2 > income Statement > net Income
17967629
Quarters > 2 > income Statement > eps
0.01
Quarters > 2 > income Statement > dividends Per Share
-8175034
Quarters > 2 > income Statement > shares Outstanding
1796762900
Quarters > 2 > income Statement > income Tax Expense
1918575
Quarters > 2 > income Statement > EBITDA
-3258826
Quarters > 2 > income Statement > operating Margin
4.299930500231232
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
7008087437
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
363566458
Quarters > 2 > balance Sheet > inventories
97071778
Quarters > 2 > balance Sheet > total Current Assets
7897451165
Quarters > 2 > balance Sheet > property Plant Equipment
797071804
Quarters > 2 > balance Sheet > total Assets
9413626269
Quarters > 2 > balance Sheet > payables
165680796
Quarters > 2 > balance Sheet > short Term Debt
175549680
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
2647510515
Quarters > 2 > balance Sheet > equity
6748973643
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
17967629
Quarters > 2 > cash Flow > depreciation
16756031
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
56524291
Quarters > 2 > cash Flow > capital Expenditures
15058034
Quarters > 2 > cash Flow > cash From Investing
78223359
Quarters > 2 > cash Flow > cash From Financing
32753836
Quarters > 2 > cash Flow > net Change In Cash
164243608
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
0.01
Quarters > 2 > ratios > PB
0.5457665327853762
Quarters > 2 > ratios > ROE
0.26622757696847626
Quarters > 2 > ratios > ROA
0.1908683060763648
Quarters > 2 > ratios > FCF
41466257
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.10876020458930334
Quarters > 2 > health Score
60
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
311699784
Quarters > 3 > income Statement > cost Of Revenue
40412554
Quarters > 3 > income Statement > gross Profit
271287230
Quarters > 3 > income Statement > operating Expenses
437053816
Quarters > 3 > income Statement > operating Income
-165766586
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-167303749
Quarters > 3 > income Statement > net Income
-165223031
Quarters > 3 > income Statement > eps
-0.10230322773672344
Quarters > 3 > income Statement > dividends Per Share
-8317199
Quarters > 3 > income Statement > shares Outstanding
1615032435
Quarters > 3 > income Statement > income Tax Expense
234328
Quarters > 3 > income Statement > EBITDA
-121474627
Quarters > 3 > income Statement > operating Margin
-53.18148889060507
Quarters > 3 > income Statement > total Other Income Expense Net
-1537163
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
6222626000
Quarters > 3 > balance Sheet > short Term Investments
1062899000
Quarters > 3 > balance Sheet > receivables
371164000
Quarters > 3 > balance Sheet > inventories
95577000
Quarters > 3 > balance Sheet > total Current Assets
7820188000
Quarters > 3 > balance Sheet > property Plant Equipment
814273389
Quarters > 3 > balance Sheet > total Assets
9407494000
Quarters > 3 > balance Sheet > payables
128363000
Quarters > 3 > balance Sheet > short Term Debt
225405000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
2661559000
Quarters > 3 > balance Sheet > equity
6725301000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-165223031
Quarters > 3 > cash Flow > depreciation
107125912
Quarters > 3 > cash Flow > change In Working Capital
-15687411
Quarters > 3 > cash Flow > cash From Operations
-32415503
Quarters > 3 > cash Flow > capital Expenditures
6961388
Quarters > 3 > cash Flow > cash From Investing
-247811918
Quarters > 3 > cash Flow > cash From Financing
-23901684
Quarters > 3 > cash Flow > net Change In Cash
-270170705
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.10230322773672344
Quarters > 3 > ratios > PB
0.4922926857474483
Quarters > 3 > ratios > ROE
-2.4567380850314358
Quarters > 3 > ratios > ROA
-1.7562916436619571
Quarters > 3 > ratios > FCF
-39376891
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-0.12632954214687553
Quarters > 3 > health Score
34
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
1009448000
Annuals > 0 > income Statement > cost Of Revenue
138441000
Annuals > 0 > income Statement > gross Profit
871007000
Annuals > 0 > income Statement > operating Expenses
1396791000
Annuals > 0 > income Statement > operating Income
-525784000
Annuals > 0 > income Statement > interest Expense
33788000
Annuals > 0 > income Statement > pretax Income
-452593000
Annuals > 0 > income Statement > net Income
-440633000
Annuals > 0 > income Statement > eps
-0.26059851553952157
Annuals > 0 > income Statement > dividends Per Share
-362925293
Annuals > 0 > income Statement > shares Outstanding
1690850000
Annuals > 0 > income Statement > income Tax Expense
263000
Annuals > 0 > income Statement > EBITDA
-312545000
Annuals > 0 > income Statement > operating Margin
-52.086288743947186
Annuals > 0 > income Statement > total Other Income Expense Net
73191000
Annuals > 0 > income Statement > currency_symbol
CNY
Annuals > 0 > balance Sheet > cash
6222626000
Annuals > 0 > balance Sheet > short Term Investments
1062899000
Annuals > 0 > balance Sheet > receivables
371164000
Annuals > 0 > balance Sheet > inventories
95577000
Annuals > 0 > balance Sheet > total Current Assets
7820188000
Annuals > 0 > balance Sheet > property Plant Equipment
814273389
Annuals > 0 > balance Sheet > total Assets
9407494000
Annuals > 0 > balance Sheet > payables
128363000
Annuals > 0 > balance Sheet > short Term Debt
225405000
Annuals > 0 > balance Sheet > long Term Debt
1018700000
Annuals > 0 > balance Sheet > total Liabilities
2661559000
Annuals > 0 > balance Sheet > equity
6725301000
Annuals > 0 > balance Sheet > currency_symbol
CNY
Annuals > 0 > cash Flow > net Income
-452593000
Annuals > 0 > cash Flow > depreciation
106260000
Annuals > 0 > cash Flow > change In Working Capital
-18067000
Annuals > 0 > cash Flow > cash From Operations
-365551000
Annuals > 0 > cash Flow > capital Expenditures
78231000
Annuals > 0 > cash Flow > cash From Investing
1111124000
Annuals > 0 > cash Flow > cash From Financing
-285595000
Annuals > 0 > cash Flow > net Change In Cash
476903000
Annuals > 0 > cash Flow > currency_symbol
CNY
Annuals > 0 > ratios > PE
-0.26059851553952157
Annuals > 0 > ratios > PB
0.5154033254422367
Annuals > 0 > ratios > ROE
-6.5518703177746245
Annuals > 0 > ratios > ROA
-4.6838509809307345
Annuals > 0 > ratios > FCF
-443782000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-0.43962839096218925
Annuals > 0 > health Score
33
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
738537000
Annuals > 1 > income Statement > cost Of Revenue
128435146
Annuals > 1 > income Statement > gross Profit
610101854
Annuals > 1 > income Statement > operating Expenses
1261256029
Annuals > 1 > income Statement > operating Income
-651154128
Annuals > 1 > income Statement > interest Expense
35031000
Annuals > 1 > income Statement > pretax Income
-644206000
Annuals > 1 > income Statement > net Income
-631263000
Annuals > 1 > income Statement > eps
-0.37000005686600596
Annuals > 1 > income Statement > dividends Per Share
-1153298
Annuals > 1 > income Statement > shares Outstanding
1706115954
Annuals > 1 > income Statement > income Tax Expense
1426000
Annuals > 1 > income Statement > EBITDA
-516554000
Annuals > 1 > income Statement > operating Margin
-88.16811182107328
Annuals > 1 > income Statement > total Other Income Expense Net
6948128
Annuals > 1 > income Statement > currency_symbol
CNY
Annuals > 1 > balance Sheet > cash
8224596000
Annuals > 1 > balance Sheet > short Term Investments
-187
Annuals > 1 > balance Sheet > receivables
276377549
Annuals > 1 > balance Sheet > inventories
119095000
Annuals > 1 > balance Sheet > total Current Assets
8765323000
Annuals > 1 > balance Sheet > property Plant Equipment
1089039000
Annuals > 1 > balance Sheet > total Assets
9919129000
Annuals > 1 > balance Sheet > payables
134904878
Annuals > 1 > balance Sheet > short Term Debt
1274364165
Annuals > 1 > balance Sheet > long Term Debt
26300000
Annuals > 1 > balance Sheet > total Liabilities
2738424000
Annuals > 1 > balance Sheet > equity
7147848684
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-644206000
Annuals > 1 > cash Flow > depreciation
92621000
Annuals > 1 > cash Flow > change In Working Capital
-243886000
Annuals > 1 > cash Flow > cash From Operations
-671340000
Annuals > 1 > cash Flow > capital Expenditures
254655000
Annuals > 1 > cash Flow > cash From Investing
666914000
Annuals > 1 > cash Flow > cash From Financing
1308000
Annuals > 1 > cash Flow > net Change In Cash
22580000
Annuals > 1 > cash Flow > currency_symbol
CNY
Annuals > 1 > ratios > PE
-0.37000005686600596
Annuals > 1 > ratios > PB
0.48931333892518086
Annuals > 1 > ratios > ROE
-8.831510401346934
Annuals > 1 > ratios > ROA
-6.364097089573087
Annuals > 1 > ratios > FCF
-925995000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-1.2538234374174888
Annuals > 1 > health Score
34
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
625404000
Annuals > 2 > income Statement > cost Of Revenue
143397000
Annuals > 2 > income Statement > gross Profit
482007000
Annuals > 2 > income Statement > operating Expenses
1252411000
Annuals > 2 > income Statement > operating Income
-770404000
Annuals > 2 > income Statement > interest Expense
17045000
Annuals > 2 > income Statement > pretax Income
-893727000
Annuals > 2 > income Statement > net Income
-886593000
Annuals > 2 > income Statement > eps
-0.5992254480201952
Annuals > 2 > income Statement > dividends Per Share
3263302
Annuals > 2 > income Statement > shares Outstanding
1479565000
Annuals > 2 > income Statement > income Tax Expense
-7134000
Annuals > 2 > income Statement > EBITDA
-808279000
Annuals > 2 > income Statement > operating Margin
-123.18501320746269
Annuals > 2 > income Statement > total Other Income Expense Net
-123323000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
8697927000
Annuals > 2 > balance Sheet > short Term Investments
313290000
Annuals > 2 > balance Sheet > receivables
127824971
Annuals > 2 > balance Sheet > inventories
65322000
Annuals > 2 > balance Sheet > total Current Assets
9299708000
Annuals > 2 > balance Sheet > property Plant Equipment
952213000
Annuals > 2 > balance Sheet > total Assets
10321158000
Annuals > 2 > balance Sheet > payables
118597000
Annuals > 2 > balance Sheet > short Term Debt
1217280000
Annuals > 2 > balance Sheet > long Term Debt
0
Annuals > 2 > balance Sheet > total Liabilities
2676831000
Annuals > 2 > balance Sheet > equity
7597101000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-893727000
Annuals > 2 > cash Flow > depreciation
68403000
Annuals > 2 > cash Flow > change In Working Capital
-75100000
Annuals > 2 > cash Flow > cash From Operations
-565554000
Annuals > 2 > cash Flow > capital Expenditures
370327000
Annuals > 2 > cash Flow > cash From Investing
-1726354000
Annuals > 2 > cash Flow > cash From Financing
3094506000
Annuals > 2 > cash Flow > net Change In Cash
942500000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.5992254480201952
Annuals > 2 > ratios > PB
0.39924548192790904
Annuals > 2 > ratios > ROE
-11.670148916014147
Annuals > 2 > ratios > ROA
-8.590053557943788
Annuals > 2 > ratios > FCF
-935881000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-1.4964422996974756
Annuals > 2 > health Score
33
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
1043033000
Annuals > 3 > income Statement > cost Of Revenue
65667000
Annuals > 3 > income Statement > gross Profit
977366000
Annuals > 3 > income Statement > operating Expenses
1140997000
Annuals > 3 > income Statement > operating Income
-181104000
Annuals > 3 > income Statement > interest Expense
2642000
Annuals > 3 > income Statement > pretax Income
-20121000
Annuals > 3 > income Statement > net Income
-64545000
Annuals > 3 > income Statement > eps
-0.03658346948444857
Annuals > 3 > income Statement > dividends Per Share
3263302
Annuals > 3 > income Statement > shares Outstanding
1764321452
Annuals > 3 > income Statement > income Tax Expense
46558000
Annuals > 3 > income Statement > EBITDA
-167203000
Annuals > 3 > income Statement > operating Margin
-17.363209025984798
Annuals > 3 > income Statement > total Other Income Expense Net
160983000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
5928716000
Annuals > 3 > balance Sheet > short Term Investments
317059000
Annuals > 3 > balance Sheet > receivables
45273000
Annuals > 3 > balance Sheet > inventories
9918000
Annuals > 3 > balance Sheet > total Current Assets
6417111000
Annuals > 3 > balance Sheet > property Plant Equipment
502366000
Annuals > 3 > balance Sheet > total Assets
7397531000
Annuals > 3 > balance Sheet > payables
84602000
Annuals > 3 > balance Sheet > short Term Debt
13504664
Annuals > 3 > balance Sheet > long Term Debt
1200564000
Annuals > 3 > balance Sheet > total Liabilities
1738612000
Annuals > 3 > balance Sheet > equity
5604559000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-20121000
Annuals > 3 > cash Flow > depreciation
32482000
Annuals > 3 > cash Flow > change In Working Capital
119525000
Annuals > 3 > cash Flow > cash From Operations
167058000
Annuals > 3 > cash Flow > capital Expenditures
167069000
Annuals > 3 > cash Flow > cash From Investing
-1729965000
Annuals > 3 > cash Flow > cash From Financing
2544807000
Annuals > 3 > cash Flow > net Change In Cash
936603000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-0.03658346948444857
Annuals > 3 > ratios > PB
0.6453422966195912
Annuals > 3 > ratios > ROE
-1.151651717824721
Annuals > 3 > ratios > ROA
-0.8725208451306252
Annuals > 3 > ratios > FCF
-11000
Annuals > 3 > ratios > Piotroski FScore
2
Annuals > 3 > ratios > fcf Percent
-0.000010546166803926625
Annuals > 3 > health Score
35
Valuation > metrics > PE
-0.002732553544192528
Valuation > metrics > PB
3.8621899847498016
Valuation > final Score
41.378100152501986
Valuation > verdict
28.7% Overvalued
Profitability > metrics > ROE
-0.5148117527401441
Profitability > metrics > ROA
-0.43088530294653726
Profitability > metrics > Net Margin
-0.08940875870006089
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.42692620559768174
Risk > metrics > Interest Coverage
-5.772375524393709
Risk > final Score
37
Risk > verdict
High
Liquidity > metrics > Current Ratio
16.77597641402572
Liquidity > metrics > Quick Ratio
16.51210504817432
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
90
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
8
Prev Profitabilities > 2
0
Prev Risks > 0
55
Prev Risks > 1
63
Prev Risks > 2
46
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:01:58.416Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-26
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-09-30
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.0027
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-19
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
AfterMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.0038
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-03-31
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
0.0014
Earnings History > 3 > eps Estimate
-
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2024-12-31
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-0.013
Earnings History > 4 > eps Estimate
-
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-09-30
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
-0.0011
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-06-30
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
-0.0094
Earnings History > 6 > eps Estimate
-
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-03-31
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
-
Earnings History > 7 > eps Actual
-0.0112
Earnings History > 7 > eps Estimate
-
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2023-12-31
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
-
Earnings History > 8 > eps Actual
-0.0079
Earnings History > 8 > eps Estimate
-
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-09-30
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-0.0085
Earnings History > 9 > eps Estimate
-
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-06-30
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-0.0331
Earnings History > 10 > eps Estimate
-
Earnings History > 10 > eps Difference
0
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-03-31
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-0.001
Earnings History > 11 > eps Estimate
-
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2022-12-31
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-0.0042
Earnings History > 12 > eps Estimate
-
Earnings History > 12 > eps Difference
0
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-09-30
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
-0.0325
Earnings History > 13 > eps Estimate
-
Earnings History > 13 > eps Difference
0
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-06-30
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
-
Earnings History > 14 > eps Actual
-0.0277
Earnings History > 14 > eps Estimate
-
Earnings History > 14 > eps Difference
0
Earnings History > 14 > surprise Percent
-
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-03-31
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
-
Earnings History > 15 > eps Actual
-0.0106
Earnings History > 15 > eps Estimate
-
Earnings History > 15 > eps Difference
0
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2021-12-31
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
-
Earnings History > 16 > eps Actual
-0.0135
Earnings History > 16 > eps Estimate
-
Earnings History > 16 > eps Difference
0
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-09-30
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
0.0261
Earnings History > 17 > eps Estimate
-
Earnings History > 17 > eps Difference
0
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2021-03-31
Earnings History > 18 > report Date
2021-06-30
Earnings History > 18 > date
2021-03-31
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
-0.0122
Earnings History > 18 > eps Estimate
0
Earnings History > 18 > eps Difference
-0.0122
Earnings History > 18 > surprise Percent
-
Earnings History > 19 > period
2020-12-31
Earnings History > 19 > report Date
2021-03-31
Earnings History > 19 > date
2020-12-31
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
-0.012
Earnings History > 19 > eps Estimate
0
Earnings History > 19 > eps Difference
-0.012
Earnings History > 19 > surprise Percent
-
Earnings History > 20 > period
2020-09-30
Earnings History > 20 > report Date
2020-12-31
Earnings History > 20 > date
2020-09-30
Earnings History > 20 > before After Market
-
Earnings History > 20 > currency
USD
Earnings History > 20 > eps Actual
-0.0034
Earnings History > 20 > eps Estimate
0
Earnings History > 20 > eps Difference
-0.0034
Earnings History > 20 > surprise Percent
-
Earnings History > 21 > period
2020-06-30
Earnings History > 21 > report Date
2020-09-30
Earnings History > 21 > date
2020-06-30
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
USD
Earnings History > 21 > eps Actual
-0.0032
Earnings History > 21 > eps Estimate
0
Earnings History > 21 > eps Difference
-0.0032
Earnings History > 21 > surprise Percent
-
Earnings History > 22 > period
2020-03-31
Earnings History > 22 > report Date
2020-06-30
Earnings History > 22 > date
2020-03-31
Earnings History > 22 > before After Market
-
Earnings History > 22 > currency
USD
Earnings History > 22 > eps Actual
-0.0306
Earnings History > 22 > eps Estimate
0
Earnings History > 22 > eps Difference
-0.0306
Earnings History > 22 > surprise Percent
-
Earnings History > 23 > period
2019-12-31
Earnings History > 23 > report Date
2020-03-31
Earnings History > 23 > date
2019-12-31
Earnings History > 23 > before After Market
-
Earnings History > 23 > currency
USD
Earnings History > 23 > eps Actual
-0.0305
Earnings History > 23 > eps Estimate
0
Earnings History > 23 > eps Difference
-0.0305
Earnings History > 23 > surprise Percent
-
Earnings History > 24 > period
2019-09-30
Earnings History > 24 > report Date
2019-12-31
Earnings History > 24 > date
2019-09-30
Earnings History > 24 > before After Market
-
Earnings History > 24 > currency
USD
Earnings History > 24 > eps Actual
-0.7124
Earnings History > 24 > eps Estimate
0
Earnings History > 24 > eps Difference
-0.7124
Earnings History > 24 > surprise Percent
-
Earnings History > 25 > period
2019-06-30
Earnings History > 25 > report Date
2019-09-30
Earnings History > 25 > date
2019-06-30
Earnings History > 25 > before After Market
-
Earnings History > 25 > currency
USD
Earnings History > 25 > eps Actual
-0.1541
Earnings History > 25 > eps Estimate
0
Earnings History > 25 > eps Difference
-0.1541
Earnings History > 25 > surprise Percent
-
Earnings History > 26 > period
2019-03-31
Earnings History > 26 > report Date
2019-06-30
Earnings History > 26 > date
2019-03-31
Earnings History > 26 > before After Market
-
Earnings History > 26 > currency
USD
Earnings History > 26 > eps Actual
-0.1203
Earnings History > 26 > eps Estimate
0
Earnings History > 26 > eps Difference
-0.1203
Earnings History > 26 > surprise Percent
-
Earnings History > 27 > period
2018-12-31
Earnings History > 27 > report Date
2019-03-31
Earnings History > 27 > date
2018-12-31
Earnings History > 27 > before After Market
-
Earnings History > 27 > currency
USD
Earnings History > 27 > eps Actual
-0.1231
Earnings History > 27 > eps Estimate
0
Earnings History > 27 > eps Difference
-0.1231
Earnings History > 27 > surprise Percent
-
Earnings History > 28 > period
2018-09-30
Earnings History > 28 > report Date
2018-12-31
Earnings History > 28 > date
2018-09-30
Earnings History > 28 > before After Market
-
Earnings History > 28 > currency
USD
Earnings History > 28 > eps Actual
-0.067
Earnings History > 28 > eps Estimate
0
Earnings History > 28 > eps Difference
-0.067
Earnings History > 28 > surprise Percent
-
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-192, a pan-FGFR inhibitor that is in a registrational trial for the treatment of solid tumor patients, including cholangiocarcinoma; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase II clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, the company develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, the company offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. The company has a clinical collaboration with ArriVent Biopharma, Inc. to evaluate the anti-tumor activity and safety of ICP-189 combined with furmonertinib in patients with advanced non-small cell lung cancer. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AShowing 2 of 6
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of InnoCare Pharma Limited
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.0027
EPS Estimate
—
EPS Difference
0
Surprise Percent
0%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.